UNSPSC 51382802: Clofezone

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C19H20N2O2.C14H21ClN2O2.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TPT3MH65LD, chemically known as 2-(4-chlorophenoxy)-n-(2-(diethylamino)ethyl)acetamide, compound with 4-butyl-1,2-diphenyltetrahydropyrazol-3,5-dione (1:1) but generally known as clofezone, which bears US NIH Compound Identifier 6433695.

UNSPSC 51382802 Clofezone is a Commodity code under which state and local governments procure pharmaceutical products, though recent solicitations under this specific code actually involve naloxone, safe drug deactivation systems, and generic multi-source pharmaceuticals rather than clofezone itself. The work includes supply of finished pharmaceutical products for public health and community health initiatives, delivered through established wholesale distribution channels or direct manufacturer relationships. Issuing bodies span county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance), with cooperative purchasing vehicles serving multiple states and local jurisdictions simultaneously.

Recent activity concentrates in Florida and the multi-state cooperative purchasing region encompassing Minnesota and Oregon. Seminole County, Florida released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a due date of July 26, 2023, requiring quarterly deliveries to the Seminole County Community Health Building and including FEMA-funded compliance requirements. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels, signaling early-stage procurement planning with no formal evaluation timeline. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson), with a proposal deadline of March 26, 2026, and contract effectiveness of July 1, 2026; evaluation weighs price competitiveness at 75 percent and requires vendors to maintain $5 million commercial general liability coverage and cGMP and DSCSA certification.